UPDATE 1-FDA approves BioCryst's intravenous flu drug

December 22, 2014 2:03 PM

3 0

Dec 22 (Reuters) - The U.S. Food and Drug Administration approved Biocryst Pharmaceuticals Inc's intravenous flu drug, sending the company's shares up nearly 10 percent in premarket trading.

The single-dose drug is for adults who have acute uncomplicated influenza and may be unable to swallow pills, such as Gilead Sciences Inc's Tamiflu, or inhale GlaxoSmithKline Plc's Relenza.

Read more

To category page